Since gemcitabine is a ready-made inhibitor of DCTD, we proposed a hypothesis to support the recommission of gemcitabine as an adjuvant therapy for malignant glioma with high DCTD expression (Fig. 7). This evidence concerns the gene DCTD and malignant glioma.